|
1
|
Crispens MA: Endometrial and ovarian
cancer in lynch syndrome. Clin Colon Rectal Surg. 25:97–102. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Neesham D: Ovarian cancer screening. Aust
Fam Physician. 36:126–128. 2007.
|
|
3
|
Lu KH: Clinical relevance of hereditary
endometrial cancer. Hereditary gynecologic cancer: risk,
prevention, and management. 1st edition. Informa Healthcare; New
York, NY: pp. 15–28. 2008
|
|
4
|
Bewtra C, Watson P, Conway T, Read-Hippee
C and Lynch HT: Hereditary ovarian cancer: a clinicopathological
study. Int J Gynecol Pathol. 11:180–187. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vasen HF, Watson P, Mecklin JP and Lynch
HT: New clinical criteria for hereditary nonpolyposis colorectal
cancer (HNPCC, Lynch syndrome) proposed by the International
Collaborative group on HNPCC. Gastroenterology. 116:1453–1456.
1999. View Article : Google Scholar
|
|
6
|
Jascur T and Boland CR: Structure and
function of the components of the human DNA mismatch repair system.
lnt J Cancer. 119:2030–2035. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harfe BD and Jinks-Robertson S: DNA
mismatch repair and genetic instability. Annu Rev Genet.
34:359–399. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kuiper RP, Vissers LE, Venkatachalam R, et
al: Recurrence and variability of germline EPCAM deletions in Lynch
syndrome. Hum Mutat. 32:407–414. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Umar A, Boland CR, Terdiman JP, et al:
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal
cancer (Lynch syndrome) and microsatellite instability. J Natl
Cancer Inst. 96:261–268. 2004. View Article : Google Scholar
|
|
10
|
Aarnio M, Sankila R, Pukkala E, et al:
Cancer risk in mutation carriers of DNA mismatch repair genes. Int
J Cancer. 81:214–218. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Watson P, Vasen HF, Menklin JP, et al: The
risk of extra-colonic, extra-endometrial cancer in the Lynch
syndrome. Int J Cancer. 123:444–449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Engel C, Loeffler M, Steinke V, et al:
Risks of less common cancers in proven mutation carriers with lynch
syndrome. J Clin Oncol. 30:4409–4415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ketabi Z, Bartuma K, Bernstein I, et al:
Ovarian cancer linked to Lynch syndrome typically presents as
early-onset, non-serous epithelial tumors. Gynecol Oncol.
121:462–465. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Watson P, Bützow R, Lynch HT, et al;
International Collaborative Group on HNPCC. The clinical features
of ovarian cancer in hereditary nonpolyposis colorectal cancer.
Gynecol Oncol. 82:223–228. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu K: Gynecological malignancy as a
‘sentinel cancer’ for women with HNPCC. Gynecol Oncol.
92:4212004.
|
|
16
|
Vasen HF, Stormorken A, Menko FH, et al:
MSH2 mutation carriers are at higher risk of cancer than MLH1
mutation carriers: a study of hereditary nonpolyposis colorectal
cancer families. J Clin Oncol. 19:4074–4080. 2001.PubMed/NCBI
|
|
17
|
Cederquist K, Emanuelsson M, Wiklund F,
Golovleva I, Palmqvist R and Grönberg H: Two Swedish founder MSH6
mutations, one nonsense and one missense, conferring high
cumulative risk of Lynch syndrome. Clin Genet. 68:533–541. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sood AK, Holmes R, Hendrix MJ and Buller
RE: Application of the National Cancer Institute International
criteria for determination of microsatellite instability in ovarian
cancer. Cancer Res. 61:4371–4374. 2001.PubMed/NCBI
|
|
19
|
Gras E, Catasus L, Argüelles R, et al:
Microsatellite instability, MLH-1 promoter hypermethylation, and
frameshift mutations at coding mononucleotide repeat
microsatellites in ovarian tumors. Cancer. 92:2829–2836. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cai KQ, Albarracin C, Rosen D, et al:
Microsatellite instability and alteration of the expression of
hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol.
35:552–559. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rosen DG, Cai KQ, Luthra R and Liu J:
Immunohistochemical staining of hMLH1 and hMSH2 reflects
microsatellite instability status in ovarian carcinoma. Mod Pathol.
19:1414–1420. 2006.PubMed/NCBI
|
|
22
|
Malander S, Rambech E, Kristoffersson U,
et al: The contribution of the hereditary nonpolyposis colorectal
cancer syndrome to the development of ovarian cancer. Gynecol
Oncol. 101:238–243. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Domanska K, Malander S, Måsbäck A and
Nilbert M: Ovarian cancer at young age: the contribution of
mismatch-repair defects in a population-based series of epithelial
ovarian cancer before age 40. Int J Gynecol Cancer. 17:789–793.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shaw PA, McLaughlin JR, Zweemer RP, et al:
Histopathologic features of genetically determined ovarian cancer.
Int J Gynecol Pathol. 21:407–411. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Piek JM, Torrenga B, Hermsen B, et al:
Histopathological characteristics of BRCA1- and BRCA2-associated
intraperitoneal cancer: a clinic-based study. Fam Cancer. 2:73–78.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Crijnen TE, Janssen-Heijnen ML, Gelderblom
H, et al: Survival of patients with ovarian cancer due to a
mismatch repair defect. Fam Cancer. 4:301–305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Watson P and Lynch HT: Cancer risk in
mismatch repair gene mutation carriers. Fam Cancer. 1:57–60. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grindedal EM, Renkonen-Sinisao L, Vasen H,
et al: Survival in women with MMR mutations and ovarian cancer: a
multicentre study in Lynch syndrome kindreds. J Med Genet.
47:99–102. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aebi S, Kurdi-Haidar B, Gordon R, et al:
Loss of DNA mismatch repair in acquired resistance to cisplatin.
Cancer Res. 56:3087–3090. 1996.PubMed/NCBI
|
|
30
|
Plumb JA, Strathdee G, Sludden J, Kaye SB
and Brown R: Reversal of drug resistance in human tumor xenografts
by 2′-deoxy-5-azacytidine-induced demethylation of the hMLHl gene
promoter. Cancer Res. 60:6039–6044. 2000.
|
|
31
|
Helleman J, van Staveren IL, Dinjens WN,
et al: Mismatch repair and treatment resistance in ovarian cancer.
BMC Cancer. 6:2012006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lindor NM, Petersen GM, Hadley DW, et al:
Recommendations for the care of individuals with an inherited
predisposition to Lynch syndrome: a systematic review. JAMA.
296:1507–1517. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brown GJ, St John DJ, Macrae FA and
Aittomäki K: Cancer risk in young women at risk of hereditary
nonpolyposis colorectal cancer: implications for gynecologic
surveillance. Gynecol Oncol. 80:346–349. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zurawski VR Jr, Orjaseter H, Anderson A
and Jellum E: Elevated serum CA 125 levels prior to diagnosis of
ovarian neoplasia: relevance for early detection of ovarian cancer.
Int J Cancer. 42:677–680. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zurawski VR Jr, Sjovall K, Schoenfeld DA,
et al: Prospective evaluation of serum CA 125 levels in a normal
population, phase I: the specificities of single and serial
determinations in testing for ovarian cancer. Gynecol Oncol.
36:299–305. 1990. View Article : Google Scholar
|
|
36
|
Skates SJ, Xu FJ, Yu YH, et al: Toward an
optimal algorithm for ovarian cancer screening with longitudinal
tumor markers. Cancer. 76(10 Suppl): 2004–2010. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Buys SS, Partridge E, Greene MH, et al;
PLCO Project Team. Ovarian cancer screening in the Prostate, Lung,
Colorectal and Ovarian (PLCO) cancer screening trial: findings from
the initial screen of a randomized trial. Am J Obstet Gynecol.
193:1630–1639. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jacobs I, Davies AP, Bridges J, et al:
Prevalence screening for ovarian cancer in postmenopausal women by
CA 125 measurement and ultrasonography. BMJ. 306:1030–1034. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bast RC Jr, Klug TL, St John E, et al: A
radioimmunoassay using a monoclonal antibody to monitor the course
of epithelial ovarian cancer. N Eng J Med. 309:883–887. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jacobs IJ, Mackay J, Menon U, Skates SJ,
Rosenthal AN and Fraser L: Familial ovarian screening - effective
or ineffective? Br J Cancer. 95(1124): 1126–1127. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Partridge E, Kreimer AR, Buys S, et al:
Ovarian cancer screening in the Prostate, Lung, Colorectal and
Ovarian Screening Trial: Results from 4 years of annual screening
in a randomized trial. Gynecol Oncol. 104(Suppl 3): abstr 10.
S2–S35. 2007.
|
|
42
|
Burke W, Daly M, Garber J, et al:
Recommendations for follow-up care of individuals with an inherited
predisposition to cancer: II. BRCA1 and BRCA2. Cancer Genetics
Studies Consortium JAMA. 227:997–1003. 1997.PubMed/NCBI
|
|
43
|
Armstrong K, Micco E, Carney A, Stopfer J
and Putt M: Racial differences in the use of BRCA1/2 testing among
women with a family history of breast or ovarian cancer. JAMA.
293:1729–1736. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rosenthal AN, Fraser L, Manchanda R, et
al: Results of annual screening in phase I of the United Kingdom
familial ovarian cancer screening study highlight the need for
strict adherence to screening schedule. J Clin Oncol. 31:49–57.
2013. View Article : Google Scholar
|
|
45
|
Burn J, Gerdes AM, Macrae F, et al; CAPP2
Investigators. Long-term effect of aspirin on cancer risk in
carriers of hereditary colorectal cancer: an analysis from the
CAPP2 randomised controlled trial. Lancet. 378:2081–2087. 2011.
View Article : Google Scholar
|
|
46
|
No authors listed. Oral contraceptive use
and the risk of endometrial cancer. The Centers for Disease Control
Cancer and steroid Hormone Study. JAMA. 249:1600–1604. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
No authors listed. The reduction in risk
of ovarian cancer associated with oral-contraceptive use. The
Cancer and Steroid Hormone Study for the Centers for Disease
Control and the National Institute of Child Health and Human
Development. N Engl J Med. 316:650–655. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Narod SA, Risch H, Moslehi R, et al: Oral
contraceptives and the risk of hereditary ovarian cancer.
Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med.
339:424–428. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tavani A, Ricci E, La Vecchia C, et al:
Influence of menstrual and reproductive factors on ovarian cancer
risk in women with and without family history of breast or ovarian
cancer. Int J Epidemiol. 29:799–802. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Whittemore AS, Balise RR, Pharoah PD, et
al: Oral contraceptive use and ovarian cancer risk among carriers
of BRCA1 or BRCA2 mutations. Br J Cancer. 91:1911–1915. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
McLaughlin JR, Risch HA, Lubinski J, et
al; Hereditary Ovarian Cancer Clinical Study Group. Reproductive
risk factors for ovarian cancer in carriers of BRCA1 or BRCA2
mutations: a case-control study. Lancet Oncol. 8:26–34. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Burke W, Petersen G, Lynch P, et al:
Recommendations for follow-up care of individuals with an inherited
predisposition to cancer. I. Hereditary nonpolyposis colon cancer.
Cancer Genetics Studies Consortium. JAMA. 277:915–919. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bertagnolli MM: Surgical prevention of
cancer. J Clin Oncol. 23:324–332. 2005. View Article : Google Scholar
|
|
54
|
Lynch HT, Watson P, Shaw TG, et al:
Clinical impact of molecular genetic diagnosis, genetic counseling,
and management of hereditary cancer. Part II: Hereditary
nonpolyposis colorectal carcinoma as a model. Cancer. 86(11 Suppl):
2457–2463. 1999. View Article : Google Scholar
|
|
55
|
Lu KH, Dinh M, Kolhmann W, et al:
Gynecologic cancer as a ‘sentinel cancer’ for women with hereditary
nonpolyposis colorectal cancer syndrome. Obstet Gynecol.
105:569–574. 2005.
|
|
56
|
Schmeler KM, Lynch HT, Chen LM, et al:
Prophylactic surgery to reduce the risk of gynecologic cancers in
the Lynch syndrome. N Engl J Med. 354:261–269. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Banno K, Kisu I, Yanokura M, et al:
Epimutation and cancer: A new carcinogenic mechanism of Lynch
syndrome (Review). Int J Oncol. 41:793–797. 2012.PubMed/NCBI
|
|
58
|
Boks DE, Trujillo AP, Voogd AC, Morreau H,
Kenter GG and Vasen HF: Survival analysis of endometrial carcinoma
associated with hereditary nonpolyposis colorectal cancer. Int J
Cancer. 102:198–200. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chen LM, Yang KY, Little SE, Cheung MK and
Caughey AB: Gynecologic cancer prevention in Lynch
syndrome/hereditary nonpolyposis colorectal cancer families. Obstet
Gynecol. 110:18–25. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kauff ND, Satagopan JM, Robson ME, et al:
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2
mutation. N Engl J Med. 346:1609–1615. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Rebbeck TR, Lynch HT, Neuhausen SL, et al;
Prevention and Observation of Surgical End Points Study Group.
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
N Engl J Med. 346:1616–1622. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Schmeler KM, Daniels MS, Soliman PT, et
al: Primary peritoneal cancer after bilateral salpingo-oophorectomy
in two patients with Lynch syndrome. Obstet Gynecol. 115:432–434.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Lynch HT, Harris RE, Lynch PM, Guirgis HA,
Lynch JF and Bardawil WA: Role of heredity in multiple primary
cancer. Cancer. 40(4 Suppl): 1849–1854. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Parker WH, Broder MS, Liu Z, et al:
Ovarian conservation at the time of hysterectomy for benign
disease. Obstet Gynecol. 106:219–226. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Niskakoski A, Kaur S, Renkonen-Sinisalo L,
et al: Distinct molecular profiles in Lynch syndrome-associated and
sporadic ovarian carcinomas. Int J Cancer. 133:2596–2608.
2013.PubMed/NCBI
|
|
66
|
Oda K: Targeting Ras-PI3K/mTOR pathway and
predictive biomarkers in endometrial cancer. Gan To Kagaku Ryoho.
38:1084–1087. 2011.(In Japanese).
|
|
67
|
Costa-Guda J, Soong CP, Parekh VI, Agarwal
SK and Arnold A: Germline and somatic mutations in cyclin-dependent
kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic
parathyroid adenomas. Horm Cancer. 4:301–307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Jürgens B, Schmitz-Dräger BJ and Schulz
WA: Hypomethylation of L1 LINE sequences prevailing in human
urothelial carcinoma. Cancer Res. 56:5698–5703. 1996.PubMed/NCBI
|
|
69
|
Domingo E, Laiho P, Ollikainen M, et al:
BRAF screening as a low-cost effective strategy for simplifying
HNPCC genetic testing. J Med Genet. 41:664–668. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Woloszynska-Read A, Zhang W, Yu J, et al:
Coordinated cancer germline antigen promoter and global DNA
hypomethylation in ovarian cancer: association with the BORIS/CTCF
expression ratio and advanced stage. Clin Cancer Res. 17:2170–2180.
2011. View Article : Google Scholar
|
